afstyla lonoctocog alfa (rch) 2000 iu powder (and diluent) for injection
csl behring australia pty ltd - lonoctocog alfa, quantity: 2000 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.
afstyla lonoctocog alfa (rch) 1000 iu powder (and diluent) for injection
csl behring australia pty ltd - lonoctocog alfa, quantity: 1000 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.
afstyla lonoctocog alfa (rch) 250 iu powder (and diluent) for injection
csl behring australia pty ltd - lonoctocog alfa, quantity: 250 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.
kovaltry octocog alfa (bhk) 3000iu powder for injection vial
bayer australia ltd - octocog alfa, quantity: 3000 iu - liquid, multipurpose - excipient ingredients: water for injections - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups. (see clinical trials section). kovaltry does not contain von willebrand factor and is not indicated in von willebrand disease.
kovaltry octocog alfa (bhk) 2000iu powder for injection vial
bayer australia ltd - octocog alfa, quantity: 2000 iu - liquid, multipurpose - excipient ingredients: water for injections - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups. (see clinical trials section). kovaltry does not contain von willebrand factor and is not indicated in von willebrand disease.
kovaltry octocog alfa (bhk) 1000iu powder for injection vial
bayer australia ltd - octocog alfa, quantity: 1000 iu - liquid, multipurpose - excipient ingredients: water for injections - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups. (see clinical trials section). kovaltry does not contain von willebrand factor and is not indicated in von willebrand disease.
kovaltry octocog alfa (bhk) 250iu powder for injection vial
bayer australia ltd - octocog alfa, quantity: 250 iu - liquid, multipurpose - excipient ingredients: water for injections - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups. (see clinical trials section). kovaltry does not contain von willebrand factor and is not indicated in von willebrand disease.
novoeight turoctocog alfa 3000 iu powder for solution for injection vial and prefilled solvent syringe
novo nordisk pharmaceuticals pty ltd - turoctocog alfa -
novoeight turoctocog alfa 2000 iu powder for solution for injection vial and prefilled solvent syringe
novo nordisk pharmaceuticals pty ltd - turoctocog alfa -
novoeight turoctocog alfa 1000 iu powder for solution for injection vial and prefilled solvent syringe
novo nordisk pharmaceuticals pty ltd - turoctocog alfa -